News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The new reagents will bring the exceptional sensitivity of the company’s liquid format 1-step RT-qPCR reagents to a freeze-dryable format
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process
An upgraded, state-of-the-art integrated app, helps easy discovery of expert surgeons for convenient in-clinic or online consultation
The Blockchain-based solution was awarded the 2021 Bionow Technical Service Award
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
Ind-Ra maintains a neutral outlook for healthcare in FY23
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Subscribe To Our Newsletter & Stay Updated
